Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin (Daptomycin for Injection) 500mg in 10ml Single Use Vials Due to Presence of Particulate Matter

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin (Daptomycin for Injection) 500mg in 10ml Single Use Vials Due to Presence of Particulate Matter

08/29/2013 12:06 PM EDT

Lexington, Mass. – Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling four lots of CUBICIN® (daptomycin for injection) to the user level due to the presence of particulate matter found in a number of vials from these lots. No adverse events have been reported to date in association with a product complaint of vials containing glass particulates.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420